[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484427":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":44,"locations":54,"responsibleParty":300,"collaborators":11,"id":302,"slug":303,"hasResults":304,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":304,"sex":310,"minAge":311,"maxAge":11,"enrollmentInfo":312,"targetDuration":11,"studyType":315,"phases":316,"briefSummary":318,"conditions":319,"keywords":11,"overallStatus":57,"whyStopped":11,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":331},{"fullName":5,"class":6},"ANRS, Emerging Infectious Diseases","OTHER_GOV",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Nirmatrelvir\u002Fr 5 days alone","EXPERIMENTAL",null,[13],"Drug: Paxlovid 5 days",{"label":15,"type":10,"description":11,"interventionNames":16},"Nirmatrelvir\u002Fr 10 days alone",[17],"Drug: Paxlovid 10 days",{"label":19,"type":10,"description":11,"interventionNames":20},"Nirmatrelvir\u002Fr 5 days + remdesivir s.d",[13,21],"Drug: Veklury",{"label":23,"type":10,"description":11,"interventionNames":24},"Nirmatrelvir\u002Fr 10 days + remdesivir s.d",[17,21],[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Paxlovid 5 days","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 5 days, orally.\n\nNirmatrelvir\u002Fr is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role.\n\nNirmatrelvir\u002Fr (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.",[19,9],[32],"Nirmatrevlir\u002Fritonavir",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Paxlovid 10 days","Nirmatrelvir\u002Fr 300mg\u002F100 mg bid will be given for 10 days, orally.",[23,15],[32],{"type":27,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Veklury","Remdesivir \"flash\", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.",[23,19],[43],"remdesivir",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":11,"email":49},"Douae Ammour","CONTACT","+33782960531","douae.ammour@inserm.fr",{"name":51,"role":47,"phone":52,"phoneExt":11,"email":53},"Chiara Fedeli","+41 (0)22 372 9817","chiara.fedeli@hug.ch",[55,73,84,98,112,126,140,154,165,176,187,198,212,226,240,255,272,286],{"facility":56,"status":57,"city":58,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Saint-André Hospital","RECRUITING","Bordeaux","33075","France","FR",{"type":63,"coordinates":64},"Point",[65,66],-0.58046,44.84124,{"lat":66,"lon":65},[69],{"name":70,"role":47,"phone":71,"phoneExt":11,"email":72},"Fabrice Bonnet, Prof. MD","+33 5 56 79 58 23","fabrice.bonnet@chu-bordeaux.fr",{"facility":74,"status":57,"city":58,"state":58,"zip":75,"country":60,"countryCode":61,"cosmosGeoPoint":76,"geoPoint":78,"contacts":79},"Pellegrin Hospital","33076",{"type":63,"coordinates":77},[65,66],{"lat":66,"lon":65},[80],{"name":81,"role":47,"phone":82,"phoneExt":11,"email":83},"Didier Neau, Prof. MD","+33 5 67 95 523","didier.neau@chu-bordeaux.fr",{"facility":85,"status":57,"city":86,"state":86,"zip":87,"country":60,"countryCode":61,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Francois Mitterrand Hospital","Dijon","21079",{"type":63,"coordinates":89},[90,91],5.01391,47.31344,{"lat":91,"lon":90},[94],{"name":95,"role":47,"phone":96,"phoneExt":11,"email":97},"Lionel Piroth, Prof. MD","+33 3 30 29 33 05","lionel.piroth@chu-dijon.fr",{"facility":99,"status":57,"city":100,"state":100,"zip":101,"country":60,"countryCode":61,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Croix Rousse Hospital","Lyon","69317",{"type":63,"coordinates":103},[104,105],4.84789,45.74906,{"lat":105,"lon":104},[108],{"name":109,"role":47,"phone":110,"phoneExt":11,"email":111},"Florence Ader, Prof. MD","+33 4 72 07 11 07","florence.ader@chu-lyon.fr",{"facility":113,"status":57,"city":114,"state":114,"zip":115,"country":60,"countryCode":61,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"La Colombière Hospital","Montpellier","34295",{"type":63,"coordinates":117},[118,119],3.87635,43.61093,{"lat":119,"lon":118},[122],{"name":123,"role":47,"phone":124,"phoneExt":11,"email":125},"Alain Makinson, Prof. MD","+33 4 67 33 95 10","a-makinson@chu-montpellier.fr",{"facility":127,"status":57,"city":128,"state":128,"zip":129,"country":60,"countryCode":61,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Hotel Dieu Hospital","Nantes","44093",{"type":63,"coordinates":131},[132,133],-1.55336,47.21725,{"lat":133,"lon":132},[136],{"name":137,"role":47,"phone":138,"phoneExt":11,"email":139},"Francois Raffi, Prof. MD","+33 2 40 08 33 51","francois.raffi@chu-nantes.fr",{"facility":141,"status":57,"city":142,"state":142,"zip":143,"country":60,"countryCode":61,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Laribosière Hospital","Paris","75010",{"type":63,"coordinates":145},[146,147],2.3488,48.85341,{"lat":147,"lon":146},[150],{"name":151,"role":47,"phone":152,"phoneExt":11,"email":153},"Sandra Devantine, Dr","+33 6 18 74 00 01","sandra.devantine@aphp.fr",{"facility":155,"status":57,"city":142,"state":142,"zip":156,"country":60,"countryCode":61,"cosmosGeoPoint":157,"geoPoint":159,"contacts":160},"Saint Antoine Hospital","75012",{"type":63,"coordinates":158},[146,147],{"lat":147,"lon":146},[161],{"name":162,"role":47,"phone":163,"phoneExt":11,"email":164},"Karine Lacombe, Prof. MD","+33 1 49 28 24 38","karine.lacombe2@aphp.fr",{"facility":166,"status":57,"city":142,"state":142,"zip":167,"country":60,"countryCode":61,"cosmosGeoPoint":168,"geoPoint":170,"contacts":171},"Pitié-Salpêtrière Hospital","75013",{"type":63,"coordinates":169},[146,147],{"lat":147,"lon":146},[172],{"name":173,"role":47,"phone":174,"phoneExt":11,"email":175},"Valérie Pourcher, Prof MD","+33 1 42 16 41 84","valerie.martinez@aphp.fr",{"facility":177,"status":57,"city":142,"state":142,"zip":178,"country":60,"countryCode":61,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"Saint Louis Hospital","75474",{"type":63,"coordinates":180},[146,147],{"lat":147,"lon":146},[183],{"name":184,"role":47,"phone":185,"phoneExt":11,"email":186},"Jean-Michel Molina, Prof. MD","+33 1 42 49 90 66","jean-michel.molina@aphp.fr",{"facility":188,"status":57,"city":142,"state":142,"zip":189,"country":60,"countryCode":61,"cosmosGeoPoint":190,"geoPoint":192,"contacts":193},"Bichat Claude-Bernard Hospital","75877",{"type":63,"coordinates":191},[146,147],{"lat":147,"lon":146},[194],{"name":195,"role":47,"phone":196,"phoneExt":11,"email":197},"Jade Ghosn, Prof. MD","+33 14 02 58 860","jade.ghosn@aphp.fr",{"facility":199,"status":57,"city":200,"state":200,"zip":201,"country":60,"countryCode":61,"cosmosGeoPoint":202,"geoPoint":206,"contacts":207},"Robert Debré Hospital","Reims","51092",{"type":63,"coordinates":203},[204,205],4.02853,49.26526,{"lat":205,"lon":204},[208],{"name":209,"role":47,"phone":210,"phoneExt":11,"email":211},"Maxime Hentzien, Prof. MD","+33 6 07 85 01 77","mhentzien@chu-reims.fr",{"facility":213,"status":57,"city":214,"state":214,"zip":215,"country":60,"countryCode":61,"cosmosGeoPoint":216,"geoPoint":220,"contacts":221},"Purpan Hospital","Toulouse","31059",{"type":63,"coordinates":217},[218,219],1.44367,43.60426,{"lat":219,"lon":218},[222],{"name":223,"role":47,"phone":224,"phoneExt":11,"email":225},"Guillaume Martin Blondel, Prof. MD","+33 5 62 74 61 46","martin-blondel.g@chu-toulouse.fr",{"facility":227,"status":57,"city":228,"state":228,"zip":229,"country":60,"countryCode":61,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Tourcoing Hospital","Tourcoing","59208",{"type":63,"coordinates":231},[232,233],3.16117,50.72391,{"lat":233,"lon":232},[236],{"name":237,"role":47,"phone":238,"phoneExt":11,"email":239},"Olivier Robineau","+33 3 20 69 46 17","orobineau@ch-tourcoing.fr",{"facility":241,"status":57,"city":242,"state":11,"zip":11,"country":243,"countryCode":244,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"Division of Infectious Diseases, Verona University Hospital","Verona","Italy","IT",{"type":63,"coordinates":246},[247,248],10.9938,45.43854,{"lat":248,"lon":247},[251],{"name":252,"role":47,"phone":253,"phoneExt":11,"email":254},"Fulvia Mazzaferri Medical Doctor","+39 0458128243","fulvia.mazzaferri@aovr.veneto.it",{"facility":256,"status":57,"city":257,"state":11,"zip":258,"country":259,"countryCode":260,"cosmosGeoPoint":261,"geoPoint":265,"contacts":266},"Drammen Hospital, Vestre Viken Hospital","Drammen","3004","Norway","NO",{"type":63,"coordinates":262},[263,264],10.20449,59.74389,{"lat":264,"lon":263},[267],{"name":268,"role":47,"phone":269,"phoneExt":270,"email":271},"Lars Heggelund Medical Doctor","+47 48285882","+47 32803000,","Lars.heggelund@vestreviken.no",{"facility":273,"status":57,"city":274,"state":11,"zip":275,"country":259,"countryCode":260,"cosmosGeoPoint":276,"geoPoint":280,"contacts":281},"Oslo University Hospital and University of Oslo","Oslo","0372",{"type":63,"coordinates":277},[278,279],10.74609,59.91273,{"lat":279,"lon":278},[282],{"name":283,"role":47,"phone":284,"phoneExt":11,"email":285},"Øyvind Molberg Medical Doctor","+47 23 07 33 24","molberg@medisin.uio.no",{"facility":287,"status":57,"city":288,"state":11,"zip":289,"country":259,"countryCode":260,"cosmosGeoPoint":290,"geoPoint":294,"contacts":295},"Vestfold Hospital Trust","Tønsberg","3103",{"type":63,"coordinates":291},[292,293],10.40762,59.26754,{"lat":293,"lon":292},[296],{"name":297,"role":47,"phone":298,"phoneExt":11,"email":299},"Oeyvind Misund Hernes MD","+47 40881602","Oyvind.misund.hernes@siv.no",{"type":301,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100484427","phase-2-optimisation-of-antiviral-therapy-in-immunocompromised-covid-19-patients-a-randomized-factorial-controlled-strategy-trial-100484427",false,"NCT05587894","OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial: the OPTICOV Study","OPTICOV","Inclusion Criteria:\n\n1. Laboratory confirmed SARS-CoV-2 infection by RT-PCR or positive antigenic test (commercialized assay)\n2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale \\\u003C5. Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).\n3. ≥ 16 years of age (for patients recruited in Italy and in Norway, ≥ 18 years of age);\n4. Immunocompromised as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the FOPH list (criteria 5: diseases\u002Ftreatments leading to immune suppression) or other immunosuppression criteria such as Severe immunosuppression (e.g., HIV infection with CD4 + T cell count \\\u003C350 \u002F µl) Neutropenia (\\\u003C1000 neutrophils \u002F µl) ≥1 week Lymphocytopenia (\\\u003C200 lymphocytes\u002Fµl) On dialysis treatment Hereditary immunodeficiencies Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \\[an equivalent dose of prednisone \\>20 mg\u002Fday \\> 3 months\\], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib. Aggressive lymphomas (all types) Acute lymphatic leukemia Acute myeloid leukemia Acute promyelocytic leukemia T prolymphocytic leukemia Primary central nervous system lymphoma Stem cell transplantation Light chain amyloidosis Chronic lymphoid leukemia Multiple myeloma Sickle cell disease Bone marrow transplant Organ transplant Being on the waiting list for an organ transplant\n5. Willing and able to comply with study requirements and restrictions as described in the informed consent form (ICF)\n6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance (LAF for participants recruited in Norway).\n7. Participant's or its legal representative's signature of the informed consent form\n\nExclusion Criteria:\n\n1. SARS-CoV-2 PCR ≥30 CT at screening\n2. Hypersensitivity to study drugs (active substance(s) or excipients)\n3. Body weight \\\u003C 40 kg\n4. AST and\u002For ALT \\> 5 times the upper limit\n5. Cirrhosis Child-Pugh score C\n6. Is taking or is anticipated to require any prohibited therapies\\*.\n7. Participation in another interventional clinical study with an investigational compound or device, including COVID-19 therapeutics, where the study intervention is performed in the 28 days preceding the inclusion and the 10 days after the inclusion. Investigators of the different clinical studies should agree on participant's inclusion.\n8. Presence of any condition for which, in the opinion of the investigator, participation would not be in participant's best interest or that could prevent, limit, or confound the protocol-specified assessments\n9. Having received antiviral treatments against SARS-CoV-2 in the 14 days before the inclusion with exception of those having received one or two doses of nirmatrevir\u002Fr in the 24h preceding the inclusion in the study.\n10. Pregnant or breastfeeding female\n\n    * Study SOPs based on recommendations from the Liverpool COVID-19 interactions, French Society for Pharmacology and Therapeutics (https:\u002F\u002Fsfpt-fr.org\u002Frecommandations-et-publications) and French Speaking Transplantation Society will be provided to guide investigators.","ALL","16 Years",{"count":313,"type":314},256,"ESTIMATED","INTERVENTIONAL",[317],"PHASE2","The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir\u002Fr)∞ versus the reference monotherapy (nirmatrelvir\u002Fr alone) and to assess the efficacy and safety of increasing the nirmatrelvir\u002Fr course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.",[320,321],"COVID-19","Immunodeficiency","2026-02-19",{"date":324,"type":325},"2026-02-23","ACTUAL",{"date":327,"type":325},"2023-04-27",{"date":329,"type":314},"2027-06-30",{"name":5,"class":6},18]